他汀联合非诺贝特治疗血脂异常冠心病患者的临床研究.docVIP

摘 要 Abstract Objectives To compare lipid levels and high-sensitive C-reactive protein (hsCRP) levels before treatment and after, and to evaluate the safety of 8 weeks’combined statin and fenofibrate therapy in patients with coronary heart disease whose triglyceride（TG） was unsatisfactorily controlled after statin monotherapy. Methods 120 patients with coronary heart disease and normal liver and kidney function who had taken Statins for more than two months (1.70mmol/L≤TG＜5.65mmol/L) were randomly selected in China Meitan General Hospital and Beijing Hospital from October 2012 to December 2013. The clinical basic data were recorded，including age，sex， history of smoking ， drinking ， hypertension and diabetes， the patients’height ， weight，and BMI (body mass index，BMI)．The patients took Fenofibrate 200mg in the morning and Statins at night orally. The patients were following up for 8 weeks during drug treatment and for an additional four weeks after trail end. SPSS 17.0 statistics software was used to compare the clinical data，and to evaluated the efficacy and safety of 8 weeks’combined statin and fenofibrate therapy. Effectiveness evaluation: 1) Changes in the rate of lipid parameters: Changes in the rate of serum lipid parameters before and after treatment (%)=[(Serum concentration after treatment – baseline serum concentratio- ns)×100%] / baseline concentrations; 2) Achievment rate: The target of lipid-lowering therapy was referenced from China Adult Dyslipidemia Prevention Guide in 2007, achievment rate = ( the number of achievment cases/ total number of cases)×100%; 3) Total effective rate: It was referenced from the guiding principles of drug cardiovascular system in guidanceprinciple of clinical study which was formulated by Bureau of drug administration of the Ministry of health in China. Total effective rate (%) =[ ( the number of excellence + the number of improvement)×100% ] / total number of cases.Any of the following items is defined as effective: The rate